Provided by Tiger Fintech (Singapore) Pte. Ltd.

Caribou Biosciences

0.7675
-0.0175-2.23%
Post-market: 0.7564-0.0111-1.45%17:20 EDT
Volume:1.01M
Turnover:751.09K
Market Cap:71.38M
PE:-0.46
High:0.7840
Open:0.7411
Low:0.7008
Close:0.7850
Loading ...

Company Profile

Company Name:
Caribou Biosciences
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
147
Office Location:
2929 7th Street,Suite 105,Berkeley,California,United States
Zip Code:
94710
Fax:
- -
Introduction:
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Directors

Name
Position
Rachel E. Haurwitz
President and Chief Executive Officer, Director
Andrew Guggenhime
Director
Natalie R. Sacks
Director
Scott Braunstein
Director

Shareholders

Name
Position
Rachel E. Haurwitz
President and Chief Executive Officer, Director
Jason V. O'Byrne
Chief Financial Officer
Barbara G. McClung
Chief Legal Officer and Corporate Secretary
Steven B. Kanner
Chief Scientific Officer